AUS
NZ
UK
CA
USA
IND
Source: sfam_photo,Shutterstock
Summary
- Novo stocks also rose to a 52-week high of US$ 14.98 on Tuesday, recording a surge of nearly 276 per cent.
- The stocks, previously trading over the counter, launched on Nasdaq on Tuesday.
- The company currently generates its revenue solely from its Canadian subsidiary, Novo Healthnet Limited.
Stocks of Novo Integrated Sciences Inc (NASDAQ:NVOS, NVOS:US) shot up by a nearly 60 per cent on Wednesday, February 24, following their move to the Nasdaq Capital Market. The stocks, previously trading over the counter, launched on Nasdaq on Tuesday.
Novo stocks also rose to a 52-week high of US$ 14.98 on Tuesday, recording a surge of nearly 276 per cent. The scrips finally simmered down to close trading at a price of US$ 6.37.
©Kalkine Group 2021
Washington-based Novo Integrated Sciences, which owns subsidiaries in the US as well as Canada, focuses in the business of primary health care services and products. The company currently generates its revenue solely from its Canadian subsidiary, Novo Healthnet Limited.
Let’s take a peek at Novo’s latest stock performance.
Novo Integrated Sciences Inc (NASDAQ:NVOS, NVOS:US)
Novo stock reportedly became a Twitter trend on Wednesday following its uplist to Nasdaq the day before and faced multiple trading halts due to its volatility since it opened.
The health care services stock was up by about 13 per cent in pre-market trading hours early on Thursday morning (7.05AM EST), and currently logs a 10-day average trading volume of over three million.
As a per a company filing, Novo director Robert Oliva purchased more than 9,000 shares this week at a price range of US$ 4.31 to US$ 4.45 apiece.
Novo stocks are up by almost 52 per cent this year. The shares post a price-to-book (P/B) ratio of 5.179 and a 30-day average trading volume of over one million, as per the data on the TMX platform.
